<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745953</url>
  </required_header>
  <id_info>
    <org_study_id>IIRP Study US 73</org_study_id>
    <nct_id>NCT00745953</nct_id>
  </id_info>
  <brief_title>Regression of Fatty Heart by Valsartan Therapy</brief_title>
  <official_title>Regression of Fatty Heart by Valsartan Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditionally, obesity is considered an indirect cause of heart disease. Obese individuals&#xD;
      typically present with a number of traditional Framingham risk factors (hypertension,&#xD;
      dyslipidemia, and type 2 diabetes), predisposing them to heart attacks and subsequent heart&#xD;
      failure. However, an emerging body of basic research revisits a hypothesis that fat is a&#xD;
      direct cardiotoxin. Under healthy conditions, most triglyceride is stored in fatty tissue&#xD;
      (adipocytes) while the amount of triglyceride stored in non-adipocyte tissues (such as the&#xD;
      pancreas, the liver, skeletal muscle, and heart) is minimal and very tightly regulated. When&#xD;
      this regulation is disrupted, intracellular triglyceride accumulates excessively in these&#xD;
      organs (&quot;steatosis&quot;) and has been implicated in activating adverse pathways which culminate&#xD;
      in irreversible cell death (&quot;lipotoxicity&quot;), leading to several well-recognized clinical&#xD;
      syndromes. These include non-alcoholic steatohepatitis (NASH), pancreatic beta-cell failure&#xD;
      in type 2 diabetes, and dilated cardiomyopathy.&#xD;
&#xD;
      It has been recently observed that angiotensin II receptor blockers (ARBs) in addition to&#xD;
      lowering blood pressure improve insulin sensitivity and decrease the risk for type 2&#xD;
      diabetes. This study will test the above theory in two study groups: Valsartan vs.&#xD;
      Hydrochlorothiazide. We hypothesize that in obese humans with elevated myocardial&#xD;
      triglycerides, blockade of the renin-angiotensin system (Valsartan group) will reduce&#xD;
      myocardial fat with improvement of insulin sensitivity and heart function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Basic science in animal models of genetic obesity have demonstrated that obese, insulin&#xD;
      resistant animals have fatty hearts with reduced functional ability. More importantly,&#xD;
      insulin sensitizing treatment of prediabetic rats delayed development of diabetes and&#xD;
      improved heart function. A primary aim of our laboratory is to translate basic animal&#xD;
      research, suggesting that excessive lipid accumulation in the myocardium is toxic, into the&#xD;
      clinical setting using cardiac magnetic resonance imaging/spectroscopy technology. The&#xD;
      results of this research may identify new biomarkers and drug targets to prevent cardiac&#xD;
      disease in obese humans.&#xD;
&#xD;
      We used our novel in vivo magnetic resonance imaging and spectroscopy technique that enables&#xD;
      quantification of triglyceride in human myocardium non-invasively, to demonstrate that obese&#xD;
      humans like obese animals are characterized by elevated fat in myocardium. We hypothesize&#xD;
      that in obese humans with elevated myocardial TG, blockade of the renin-angiotensin system&#xD;
      will reduce myocardial fat with improvement of insulin sensitivity and heart function.&#xD;
&#xD;
      The aims of this study are to test if in obese people with impaired glucose tolerance (IGT):&#xD;
&#xD;
      Aim 1) Valsartan treatment will reduce myocardial fat and will improve heart geometry and&#xD;
      function,&#xD;
&#xD;
      Aim 2) therapy with thiazide diuretic hydrochlorothiazide (HCTZ) treatment will elevate&#xD;
      myocardial fat.&#xD;
&#xD;
      We are planning to test the action of Valsartan versus HCTZ as we expect that these drugs&#xD;
      cause opposite metabolic effects. The landmark trial ALLHAT (Antihypertensive and&#xD;
      Lipid-Lowering Treatment to Prevent Heart Attack Trial) has refocused attention to the&#xD;
      thiazide-type diuretics as the first-line therapy for most patients with hypertension.&#xD;
      Despite proven reduction in cardiovascular outcomes and low costs, there is on-going concern&#xD;
      that one of the major side effect of the thiazides-glucose intolerance-may fuel the current&#xD;
      U.S. epidemic of type 2 diabetes. Despite of efficacy and low cost thiazide diuretics are&#xD;
      long known to cause insulin resistance, impaired glucose tolerance, and precipitation of&#xD;
      overt diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial triglyceride levels</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic triglyceride levels, insulin sensitivity, abdominal fat mass</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Lipotoxicity</condition>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will determine if blockade of the renin-angiotensin system reduces myocardial fat levels and improves insulin sensitivity. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 &amp; 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, &amp; 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 &amp; 3 are needed for the adjustment of medication to the final dose level. During visits 4 &amp; 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will determine if thiazide diuretics elevate myocardial triglyceride levels. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 &amp; 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, &amp; 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 &amp; 3 are needed for the adjustment of medication to the final dose level. During visits 4 &amp; 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan 320mg PO daily for 8 months</description>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 25mg PO daily for 8 months</description>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <other_name>HCTZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prediabetic individuals with impaired glucose tolerance (2 hr postprandial glucose &gt;&#xD;
             140mg/dL) or having 3 of 5 Metabolic Syndrome criteria:&#xD;
&#xD;
               1. Fasting glucose &gt; 100mg/dL;&#xD;
&#xD;
               2. Waist circumference: men &gt; 102cm, women &gt; 88cm (confirmed with abdominal MRI);&#xD;
&#xD;
               3. HDL: men &lt; 40mg/dL, women &lt; 50mg/dL;&#xD;
&#xD;
               4. Triglycerides &gt; 150mg/dL;&#xD;
&#xD;
               5. Blood pressure &gt; 130/80mmHg;&#xD;
&#xD;
          -  Elevated hepatic triglycerides (&gt;5.5%) and myocardial triglycerides (&gt;0.6%)&#xD;
&#xD;
          -  Elevated blood triglycerides &gt;150mg/dL&#xD;
&#xD;
          -  Age &lt; 50 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetes mellitus&#xD;
&#xD;
          -  Prior exposure to renin system blockers or HCTZ&#xD;
&#xD;
          -  BP &gt; 160/100mmHg&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Metallic implants in body&#xD;
&#xD;
          -  Pregnant or planning to become pregnant&#xD;
&#xD;
          -  Prior exposure to statin medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald G Victor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lidia S Szczepaniak, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 29, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2019</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ildiko Lingvay, MD</name_title>
    <organization>University of Texas Southwestern Medical Center</organization>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Lipotoxicity</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Myocardial triglyceride levels</keyword>
  <keyword>Hepatic triglyceride levels</keyword>
  <keyword>Magnetic resonance spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

